Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
97 GBX | +4.86% | -7.62% | -15.65% |
May. 14 | Headlam warns of loss; EnSilica predicts revenue rise | AN |
May. 14 | Celadon Pharmaceuticals Plc Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Financials (USD)
Sales 2021 | - | Sales 2022 | 0.02 | Capitalization | 31.14M |
---|---|---|---|---|---|
Net income 2021 | - | Net income 2022 | -17M | EV / Sales 2021 * | - |
Net cash position 2021 | 4.46M | Net cash position 2022 | 429K | EV / Sales 2022 | 1,279,759,792 x |
P/E ratio 2021 * |
-
| P/E ratio 2022 |
-1.71
x | Employees | 24 |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 35.15% |
1 day | +2.70% | ||
1 week | -9.52% | ||
Current month | -3.06% | ||
1 month | -17.39% | ||
3 months | -13.64% | ||
6 months | -13.64% | ||
Current year | -17.39% |
Managers | Title | Age | Since |
---|---|---|---|
James Short
FOU | Founder | 55 | 17-12-31 |
Jonathan Turner
DFI | Director of Finance/CFO | 46 | 23-01-16 |
Iqbal Gill
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
David Firth
BRD | Director/Board Member | 62 | - |
Ian Anton
CHM | Chairman | 64 | 22-03-27 |
Robert Barr
BRD | Director/Board Member | 65 | 22-03-27 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-21 | 97 | +4.86% | 17 763 |
24-05-20 | 92.5 | -5.13% | 14,591 |
24-05-17 | 97.5 | -2.50% | 12,321 |
24-05-16 | 100 | -2.44% | 7,676 |
24-05-15 | 102.5 | -2.38% | 4,233 |
Delayed Quote London S.E., May 21, 2024 at 06:00 am EDT
More quotes1st Jan change | Capi. | |
---|---|---|
-17.39% | 75.46M | |
+34.35% | 705B | |
+30.68% | 583B | |
-3.49% | 364B | |
+20.15% | 332B | |
+6.19% | 291B | |
+15.66% | 238B | |
-3.35% | 210B | |
+10.35% | 209B | |
+9.21% | 169B |
- Stock Market
- Equities
- CEL Stock